July 14, 2022

MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the
appointment of Ms. Pascale Nini to the Board of Directors.

June 6, 2022

MedMira Receives Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt
of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.

May 27, 2022
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.

May 20, 2022
VYRATM Product Line Update
Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRATM product line.

May 12, 2022

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the
achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo®
Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP).

March 31, 2022

MedMira Reports Second Quarter Results FY2022
Halifax, Nova Scotia, March 31, 2022 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2022.

March, 2022

Corporate update March 2022

March 9, 2022

MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trial underway in Canada.

February 8, 2022

MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
Halifax, Nova Scotia, 8 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the
CE mark for its REVEALCOVID-19® PLUS Total Antibody Test. The test will be available in Europe and
any countries accepting the CE mark. MedMira offers its tests in a single pack for individual use and bulk
packaging for standard screening.

February 4, 2022

MedMira Provides a Pre-Annual General Meeting Update
Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a preAnnual General Meeting (AGM) update on its regulatory and product development progress. This includes its COVID-19 and its infectious disease products with the latest pre-submission for MedMira’s HCV Rapid Test to the FDA. This update serves the purpose to inform all shareholders of any potentially discussed topics during the physical AGM meeting held on this day.

November 29, 2021

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
Halifax, Nova Scotia, November 29, 2021 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2021.

March 4, 2021

Product and Regulatory Update on MedMira’s COVID-19 Product Family
Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of
its product portfolio and outlines the company’s COVID-19 market and regulatory plan.

January 29, 2021

Progress Update on MedMira’s COVID-19 Product Family
Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection.

December 31, 2020

MedMira Announces Product Update
Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™ PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19™ PLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19™ Total Antibody Test that addresses the total antibody testing demands arising from recent developments in COVID-19 vaccines across global markets.

December 24, 2020

MedMira Reports First Quarter Results FY2021
Halifax, Nova Scotia, December 24, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020.

December 1, 2020

MedMira Reports FY2020 Fourth Quarter and Year End Financial Results
Halifax, Nova Scotia, November 30, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results forthe financial year ended July 31, 2019.

June 30, 2020

Management’s Discussion & Analysis For the nine months ended April 30, 2020
This document contains forward looking statements, such as statements regarding future sales opportunities in various global regions and financing initiatives that are based on current expectations of management. These statements involve uncertainties and risks, including MedMira Inc.’s (“MedMira” or the “Company”) ability to obtain and/or access additional financing with acceptable terms, and delays in anticipated product sales.

June 30, 2020

Condensed Interim Consolidated Financial Statements For the nine months ended April 30, 2020 and April 30, 2019 (Unaudited – Prepared by Management)
In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the period ending April 30, 2020.

June 29, 2020

MedMira Reports Third Quarter Results FY2020
Halifax, Nova Scotia, June 29, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020.

May 27, 2020

MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.
Halifax, Nova Scotia, 27 May, 2020 – MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process.

May 21, 2020

MedMira Announces Progress Update of its REVEALCOVID-19TM Total Antibody test including CE mark
Halifax, Nova Scotia, 21. May, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID- 19TM Total Antibody Test.

April 23, 2020

MedMira Announces Notification Submission to US FDA Emergency Use Authorization
MedMira Inc. announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing.

April 15, 2020

MedMira Announces Development of COVID-19 Point-of-Care Antibody Test
MedMira Announces Update on Development of Point-of-Care Antibody Test.

March 31, 2020

MedMira Reports Second Quarter Results
MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended March 31, 2020.